CNS & Neurological Disorders-Drug Targets

Papers
(The H4-Index of CNS & Neurological Disorders-Drug Targets is 17. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
ArticleCitations
Neuroprotection of Rotenone-Induced Parkinsonism by Ursolic Acid in PD Mouse Model55
Scopolamine, a Toxin-Induced Experimental Model, Used for Research in Alzheimer’s Disease48
Inflammation and Mitochondrial Dysfunction in Autism Spectrum Disorder37
When Sick Brain and Hopelessness Meet: Some Aspects of Suicidality in the Neurological Patient34
Benzodiazepines and Sleep Architecture: A Systematic Review31
Role of Calcium Homeostasis in Ischemic Stroke: A Review30
Neurodegenerative Diseases and Flavonoids: Special Reference to Kaempferol28
MAPK: A Key Player in the Development and Progression of Stroke26
Autoimmune Encephalitis: Current Knowledge on Subtypes, Disease Mechanisms and Treatment24
Prospective Role of Polyphenolic Compounds in the Treatment of Neurodegenerative Diseases23
Role of Vitamins in Neurodegenerative Diseases: A Review21
Arachidonic Acid Derivatives and Neuroinflammation20
Stingless Bee Honey Reduces Anxiety and Improves Memory of the Metabolic Disease-induced Rats19
Detection, Treatment Planning, and Genetic Predisposition of Bruxism: A Systematic Mapping Process and Network Visualization Technique19
ATP-sensitive Potassium Channel Subunits in Neuroinflammation: Novel Drug Targets in Neurodegenerative Disorders18
Speech as a Biomarker for Depression17
Levodopa Therapy for Parkinson's Disease: History, Current Status and Perspectives17
Role of Brain-Gut-Microbiota Axis in Depression: Emerging Therapeutic Avenues17
Current Strategies and Novel Drug Approaches for Alzheimer Disease17
Persons with Co-Existing Neurological Disorders: Risk Analysis, Considerations and Management in COVID-19 Pandemic17
0.043087005615234